Literature DB >> 18550098

Renal masses--to treat or not to treat? If that is the question are contemporary biomarkers the answer?

Robert G Uzzo.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18550098      PMCID： PMC2843549          DOI： 10.1016/j.juro.2008.04.124

Source DB:  PubMed          Journal:  J Urol        ISSN： 0022-5347            Impact factor:   7.450


× No keyword cloud information.
  6 in total

1.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

2.  Evidence based medicine: what it is and what it isn't.

Authors:  D L Sackett; W M Rosenberg; J A Gray; R B Haynes; W S Richardson
Journal:  BMJ       Date:  1996-01-13

3.  Enhancing renal masses with zero net growth during active surveillance.

Authors:  David A Kunkle; Paul L Crispen; David Y T Chen; Richard E Greenberg; Robert G Uzzo
Journal:  J Urol       Date:  2007-03       Impact factor: 7.450

4.  Delayed intervention of sporadic renal masses undergoing active surveillance.

Authors:  Paul L Crispen; Rosalia Viterbo; Eric B Fox; Richard E Greenberg; David Y T Chen; Robert G Uzzo
Journal:  Cancer       Date:  2008-03-01       Impact factor: 6.860

Review 5.  Excise, ablate or observe: the small renal mass dilemma--a meta-analysis and review.

Authors:  David A Kunkle; Brian L Egleston; Robert G Uzzo
Journal:  J Urol       Date:  2008-02-20       Impact factor: 7.450

Review 6.  Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers.

Authors:  Paul L Crispen; Stephen A Boorjian; Christine M Lohse; Bradley C Leibovich; Eugene D Kwon
Journal:  Cancer       Date:  2008-08-01       Impact factor: 6.860
  6 in total
  4 in total

Review 1.  Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis.

Authors:  Marc C Smaldone; Alexander Kutikov; Brian L Egleston; Daniel J Canter; Rosalia Viterbo; David Y T Chen; Michael A Jewett; Richard E Greenberg; Robert G Uzzo
Journal:  Cancer       Date:  2011-07-15       Impact factor: 6.860

2.  The changing face of renal-cell carcinoma.

Authors:  Gennady Bratslavsky; Ziya Kirkali
Journal:  J Endourol       Date:  2010-05       Impact factor: 2.942

3.  Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score.

Authors:  Alexander Kutikov; Marc C Smaldone; Brian L Egleston; Brandon J Manley; Daniel J Canter; Jay Simhan; Stephen A Boorjian; Rosalia Viterbo; David Y T Chen; Richard E Greenberg; Robert G Uzzo
Journal:  Eur Urol       Date:  2011-04-01       Impact factor: 20.096

Review 4.  Active surveillance of small renal masses.

Authors:  Marc C Smaldone; Anthony T Corcoran; Robert G Uzzo
Journal:  Nat Rev Urol       Date:  2013-04-09       Impact factor: 14.432
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.